Dr. Tara Gangadhar on Single-Agent Versus Dual Immunotherapy Approaches in Melanoma

Tara Gangadhar, MD

Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.

Tara Gangadhar, MD, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania, discusses the preference toward front-line single agent immunotherapy in the treatment of melanoma. Gangadhar says this preference toward single-agent immunotherapy is due to a lack of evidence supporting the use of a combination immunotherapy approach. The other reason a dual approach is less utilized in melanoma patients is due to the significant increase in toxicities.